Drugs / masofaniten
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05295927 | Mar → Sep 2022 | prostate neoplasm | Janssen Research & Development, LLC | Terminated | No outcome recorded |
| Phase 1 | NCT04421222 | Jun 2020 → Oct 2024 | prostate cancer | ESSA Pharmaceuticals | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05075577 | Dec 2021 → Oct 2024 | prostate cancer | ESSA Pharmaceuticals | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06312670 | May 2024 → Jan 2025 | metastatic prostate carcinoma, prostate adenocarcinoma | Pedro Barata, MD, MSc | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | masofaniten | “Masofaniten (EPI-7386) is a next-generation aniten with promising activity and safety in patients with metastatic castrate-resistant prostate cancer (mCRPC).” PMID 41467749 ↗ Jan 2026 |
| Known as | EPI-7386 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05075577 ↗ |
| Known as | Masofanitene | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095106 ↗ |
| Action | Inhibit | “Anitens are a family of oral N-terminal domain inhibitors of the androgen receptor (AR).” PMID 41467749 ↗ Jan 2026 |
| Modality | Small molecule | — CHEMBL5095106 ↗ |
| Route | Oral | “Once daily oral dose of EPI-7386” NCT04421222 ↗ |
| Target | AR | “Anitens are a family of oral N-terminal domain inhibitors of the androgen receptor (AR).” PMID 41467749 ↗ Jan 2026 |